Episode 185 -June 5, 2026

Biotech industry performance currently faces headwinds as capital migrates toward AI-driven sectors, though long-term sector recovery remains supported by robust M&A activity. Legislative proposals like the Biotech Investment National Security Act threaten to restrict global collaboration and limit U.S. patient access to international innovation, despite valid concerns regarding manufacturing supply chain security. Recent clinical data from ASCO highlights significant breakthroughs, including PD-1 VEGF bispecifics showing survival benefits in lung cancer and Revolution Medicine’s RAS inhibitor demonstrating efficacy in pancreatic ductal adenocarcinoma. Furthermore, the shift toward CDK4-specific inhibitors and in vivo CAR-T therapies marks a pivotal evolution in oncology, offering potential improvements over current standards of care. Meanwhile, the FDA’s leadership transition signals a potential return to regulatory flexibility and increased reliance on advisory committees, providing cautious optimism for the future of orphan drug development.